［1］FREITES MA,SANTANA N,ARIAS SS,et al.Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies .CTCAE versión 5.0 evaluación de la gravedad de los eventos adversos dermatológicos de las terapiasantineoplásicas ［J］.Actas Dermo-Sifiliográficas,2021,112(1):90-92.
［2］JING Y,ZHANG YC,WANG J,et al.Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy ［J］.Journal of the National Cancer Institute,2021,113(10):1396-1404.
［3］DOUGLAS B JOHNSON,CAROLINE A NEBHAN,JAVID J MOSLEHI,et al.Immune-checkpoint inhibitors:long-term implications of toxicity ［J］.Nature Reviews Clinical Oncology,2022,19(4):254-267.
［4］GE XX,JIANG WP,LI HQ,et al.Immune-related adverse events and outcomes among pan-cancer patients receiving immune checkpoint inhibitors:A monocentric real-world observational study［J］.Cancer Med,2023,12(18):18491-18502.
［5］MANUEL RAMOS-CASALS,JULIE R BRAHMER,MARGARET K CALLAHAN,et al.Immune-related adverse events of checkpoint inhibitors ［J］.Nature Reviews Disease Primers,2020,6(1):38.
［6］NAMRATA SINGH,ANNE M HOCKING,JANE H BUCKNER.Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity ［J］.Immunol Rev,2023,318(1):81-88.
［7］DOUGLASB JOHNSON,JUSTIN M BALKO,MARGARET L COMPTON,et al.Fulminant myocarditis with combination immune checkpoint blockade［J］.New England Journal of Medicine,2016,375(18):1749-1755.
［8］ALEXANDER X LOZANO,AADEL A CHAUDHURI,AISHWARYA NENE,et al.T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma［J］.Nat Med,2022,28(2):353-362.
［9］ADRIENNE M LUOMA,SUO SB,HANNAH L WILLIAMS,et al.Molecular pathways of colon inflammation induced by cancer immunotherapy［J］.Cell,2020,182(3):655-671.
［10］YUKIHIRO TOI,SHUNICHI SUGAWARA,JUN SUGISAKA,et al.Profiling preexisting antibodies in patients treated with anti–PD-1 therapy for advanced non–small cell lung cancer［J］.JAMA Oncology,2019,5(3):376-383.
［11］OMAR HASAN ALI,DAVID BOMZE,SANDRA S RING,et al.BP180-specific IgG is associated with skin adverse events,therapy response,and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors ［J］.Journal of the American Academy of Dermatology,2020,82(4):854-861.
［12］SHANNON M LIUDAHL,LISA M COUSSENS.B cells as biomarkers:predicting immune checkpoint therapy adverse events ［J］.The Journal of Clinical Investigation,2018,128(2):577-579.
［13］KAVITA M DHODAPKAR,ALYSSA DUFFY ,MADHAV V DHODAPKAR.Role of B cells in immune-related adverse events following checkpoint blockade ［J］.Immunol Rev,2023,318(1):89-95.
［14］SU Y LIM, JENNY H LEE, TUBA N GIDE,et al.Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1 based immunotherapy circulating cytokines predict immunotherapy toxicity ［J］.Clinical Cancer Research,2019,25(5):1557-1563.
［15］WANG M, ZHAI XY, LI J,et al.The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors［J］.Front Immunol,2021,12:670391.
［16］SANJEEV MARIATHASAN,SHANNON J TURLEY,DOROTHEE NICKLES,et al.TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells［J］.Nature,2018,554(7693):544-548.
［17］JIAO SP,SUMIT K SUBUDHI,ANA APARICIO,et al.Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy［J］.Cell,2019,179(5):1177-1190.
［18］JEE HYE KANG,JEFFREY A BLUESTONE,ARABELLA YOUNG.Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines［J］.Trends in Immunology,2021,42(4):293-311.
［19］KARLA A LEE,HEATHER SHAW,VRONIQUE BATAILLE,et al.Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity［J］.Journal for ImmunoTherapy of Cancer,2020,8(2):e000577.
［20］MILES C ANDREWS,CONNIE PM DUONG,VANCHESWARAN GOPALAKRISHNAN,et al.Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade［J］.Nature Medicine,2021,27(8):1432-1441.
［21］ALESSIOCORTELLINI,MELISSA BERSANELLI,DANIELE SANTINI,et al.Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors:A multicentre analysis of immune-related adverse events［J］.Eur Cancer,2020,128:17-26.
［22］SEOHYUN KIM,JEONG UK LIM.Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer:systematic review of characteristics,incidence,risk factors,and management［J］.Thorac Dis,2022,14(5):1684-1695.
［23］ALEJANDRO MERAZ-MUOZ,EITAN AMIR,PAMELA NG,et al.Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence,risk factors and outcomes ［J］.Journal for Immunother Therapy of Cancer,2020,8(1):e000467.
［24］NAOTO OKADA,RIE MATSUOKA,TAKUMI SAKURADA,et al.Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study ［J］.Sci Rep,2020,10(1):13773.
［25］MEGHANA KESIREDDY,ALISSA MARR,MAKAYLA SCHISSEL,et al.A retrospective analysis of immune checkpoint inhibitors in patients with preexisting organ dysfunction ［J］.Cancer,2023,129(22):3603-3619.
［26］SATYA DAS,DOUGLAS B JOHNSON.Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors［J］.Journal for Immunother Therapy of Cancer,2019,7(1):306.
［27］YOSHIHIKOSAKATA,KODAI KAWAMURA,KAZUYA ICHIKADO,et al.The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment［J］.Lung Cancer,2019,130:159-161.
［28］KHOJA L,DAY D,WEI WCT,et al.Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors:a systematic review ［J］.Annals of Oncology,2017,28(10):2377-2385.
［29］SAEKA EGAMI,HITOSHI KAWAZOE,HIRONOBU HASHIMOTO,et al.Absolute lymphocyte count predicts immune-related adverse events in patients with non-small-cell lung cancer treated with nivolumab monotherapy:A multicenter retrospective study［J］.Frontiers in Oncology,2021,11:618570.
［30］CHU XL,ZHAO J,ZHOU J,et al.Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors［J］.Lung Cancer,2020,150:76-82.
［31］LEE PY,KELLYNN QI XUAN OEN,GRACE RUI SI LIM,et al.Neutrophil-to-lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade:A case-control study［J］.Cancers,2021,13(6):1308.
［32］SAEKA EGAMI,HITOSHI KAWAZOE,HIRONOBU HASHIMOTO,et al.Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study［J］.Journal of Cancer,2021,12(7):2105-2112.
［33］KEITARO SHIMOZAKI,YASUTAKA SUKAWA,YASUNORI SATO,et al.Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data ［J］.Future Oncology,2021,17(20):2593-2603.
［34］AAMIR-REZA ABOLHASSANI,GEROLD SCHULER,MICHAEL CONSTANTIN KIRCHBERGER,et al.C-reactive protein as an early marker of immune-related adverse events ［J］.Journal of Cancer Research and Clinical Oncology,2019,145(10):2625-2631.
［35］JENNA L COLLIER,KRISTEN E PAUKEN,CATHERINE A A LEE,et al.Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice ［J］.Journal of Exp Med,2023,220(10):e20221920.
［36］JARED OSTMEYER,JASON Y PARK,MITCHELL S VON ITZSTEIN,et al.T-cell tolerant fraction as a predictor of immune-related adverse events［J］.Journal of Immunother Cancer,2023,11(8):e006437.
［37］ALEXANDER X LOZANO,AADEL A CHAUDHURI,AISHWARYA NENE,et al.T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma ［J］.Nature Medicine,2022,28(2):353-362.
［38］JING Y,LIU J,YE YQ,et al.Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy ［J］.Nature Communications,2020,11(1):4946.
［39］CHIAKI KURIMOTO,HIDEFUMI INABA,HIROYUKI ARIYASU,et al.Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors ［J］.Cancer Science,2020,111(5):1468-1477.
［40］SALAHALDIN A TAHIR,GAO JJ,YUJI MIURA,et al.Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities ［J］.Proceedings of the National Academy of Sciences,2019,116(44):22246-22251.
［41］AMANDA LEITER,SACHA GNJATIC,MARY FOWKES,et al.A common pituitary autoantibody in two patients with immune checkpoint inhibitor-mediated hypophysitis:zcchc8［J］.AACE Clinical Case Reports,2020,6(4):e151-e160.
［42］PRADNYA D PATIL,MAURICIO BUROTTO,VAMSIDHAR
VELCHETI.Biomarkers for immune-related toxicities of checkpoint inhibitors:current progress and the road ahead ［J］.Expert Review of Molecular Diagnostics,2018,18(3):297-305.
［43］PHILIP FRIEDLANDER,KEVIN WOOD,KARL WASMANN,et al.A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab ［J］.Journal for Immunother Cancer,2018,6(1):90.
［44］MARCUS WLFFER,FLORIAN BATTKE,MARTIN SCHULZE,et al.Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma ［J］.Cancers,2022,14(2):302.
［45］AFAF ABED,NGIE LAW,LESLIE CALAPRE,et al.Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy ［J］.European Journal of Cancer,2022,172:98-106.
［46］OMAR HASAN ALI,FIAMMA BERNER,DAVID BOMZE,et al.Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors ［J］.European Journal of Cancer,2019,107:8-14.
［47］LAURA C CAPPELLI,MEHMET T DORAK,MARIA P BETTINOTTI,et al.Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis ［J］.Rheumatology (Oxford),2019,58(3):476-480.
［48］ANGELIKI M STAMATOULI,ZOE QUANDT,ANA LUISA PERDIGOTO,et al.Collateral damage:insulin-dependent diabetes induced with checkpoint inhibitors［J］.Diabetes,2018,67(8):1471-1480.
［49］GUAN YP,WANG J.Difficulty in oxicity management of tumor immunotherapy ［J］.Journal of Practical Oncology,2022,(06):490-494.
［50］ZHOU CC,WANG J,BU H,et al.Expert consensus on immune checkpoint inhibitor therapy for non-small cell lung cancer in China［J］.Chinese Journal of Lung Cancer,2020,(02):65-76.
［51］CHRISTOPHER CLUXTON, JARUSHKA NAIDOO.Prospective clinical trials to advance the study of immune checkpoint inhibitor toxicity ［J］.Curr Oncol,2023,30(7):6862-6871.
［52］CHEN MT,MA LL,YU HQ,et al.JK5G postbiotics attenuate immune-related adverse events in NSCLC patients by regulating gut microbiota:a randomized controlled trial in China ［J］.Front Oncol,2023,13:1155592.